Noxopharm Ltd has released a press release.
DARRT-2 Trial Efficacy Phase to Commence
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Noxopharm
- NOX Pipeline Boosted by $1.5M Grant to Hudson Institute
- September 2022 Quarterly Activities Report and Appendix 4C
- Novel Dual-cell Therapy Results in Pancreatic Cancer
- Response to ASX Price Query
- June 2022 Quarterly Activities Report and Appendix 4C
Later from Noxopharm
- December 2022 Quarterly Activities Report and Appendix 4C
- Appendix 4D and Half Year 2023 Financial Report
- Noxopharm Announces Novel mRNA Vaccine Enhancer
- Noxopharm to Prioritise Cutting-Edge Chroma & Sofra Programs
- March 2023 Quarterly Activities Report and Appendix 4C
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm